Targeting p110gamma in gastrointestinal cancers: Attack on multiple fronts

Frontiers in Physiology

Volumn 5, Issue OCT, 2014, Pages

  Falasca, Marco ^a   Maffucci, Tania ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Angiogenesis; Cancer; HCC; Inflammation; Metastasis; P110 ; PDAC; Phosphoinositide 3 kinase

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; DUVELISIB; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOINOSITIDE 3 KINASE CATALYTIC SUBUNIT P110GAMMA; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; GENE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PATHOGENESIS; PIK3CG GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84908376802     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00391     Document Type: Review

References (113)

1. Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., et al. (2014). Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407-411. doi: 10.1038/nature13444
2. Antonioli, L., Blandizzi, C., Pacher, P., and Haskó, G. (2013). Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13, 842-857. doi: 10.1038/nrc3613
3. Apte, M. V., Wilson, J. S., Lugea, A., and Pandol, S. J. (2013). A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 144, 1210-1219. doi: 10.1053/j.gastro.2012.11.037
4. Attoub, S., De Wever, O., Bruyneel, E., Mareel, M., and Gespach, C. (2008). The transforming functions of PI3-kinase-γ are linked to disruption of intercellular adhesion and promotion of cancer cell invasion. Ann. N.Y. Acad. Sci. 1138, 204-213. doi: 10.1196/annals.1414.027
5. Basen-Engquist, K., and Chang, M. (2011). Obesity and cancer risk: recent review and evidence. Curr. Oncol. Rep. 13, 71-76. doi: 10.1007/s11912-010-0139-7
6. Becattini, B., Marone, R., Zani, F., Arsenijevic, D., Seydoux, J., Montani, J. P., et al. (2011). PI3Kγ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 108, E854-E863. doi: 10.1073/pnas.1106698108
7. Beer-Hammer, S., Zebedin, E., von Holleben, M., Alferink, J., Reis, B., Dresing, P., et al. (2010). The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J. Leuk. Biol. 87, 1083-1095. doi: 10.1189/jlb.0809585
8. Bénistant, C., Chapuis, H., and Roche, S. (2000). A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19, 5083-5090. doi: 10.1038/sj.onc.1203871
9. Bethea, T. N., Kitahara, C. M., Sonderman, J. S., Patel, A. V., Harvey, C., Knutsen, S. F., et al. (2014). A pooled analysis of body mass index and pancreatic cancer mortality in African, Americans. Cancer Epidemiol. Biomarkers Prev. 23, 2119-2125. doi: 10.1158/1055-9965.EPI-14-0422
10. Bondar, V. M., Sweeney-Gotsch, B., Andreeff, M., Mills, G. B., and McConkey, D. J. (2002). Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 1, 989-997.
11. Borena, W., Strohmaier, S., Lukanova, A., Bjørge, T., Lindkvist, B., Hallmans, G., et al. (2012). Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int. J. Cancer 131, 193-200. doi: 10.1002/ijc.26338
12. Brand, T. M., and Wheeler, D. L. (2012). KRAS mutant colorectal tumors: past and present. Small GTPases 3, 34-39. doi: 10.4161/sgtp.18751
13. Brazzatti, J. A., Klingler-Hoffmann, M., Haylock-Jacobs, S., Harata-Lee, Y., Niu, M., Higgins, M. D., et al. (2012). Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis. Oncogene 31, 2350-2361. doi: 10.1038/onc.2011.414
14. Brenner, H., Kloor, M., and Pox, C. P. (2014). Colorectal cancer. Lancet 383, 1490-1502. doi: 10.1016/S0140-6736(13)61649-9
15. Calle, E. E., Rodriguez, C., Walker-Thurmond, K., and Thun, M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348, 1625-1638. doi: 10.1056/NEJMoa021423
16. Carter, H., Samayoa, J., Hruban, R. H., and Karchin, R. (2010). Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). Cancer Biol. Ther. 10, 582-587. doi: 10.4161/cbt.10.6.12537
17. Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., et al. (1997). Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276, 1848-1850. doi: 10.1126/science.276.5320.1848
18. Czauderna, F., Fechtner, M., Aygün, H., Arnold, W., Klippel, A., Giese, K., et al. (2003). Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res. 31, 670-682. doi: 10.1093/nar/gkg141
19. Del Prete, A., Vermi, W., Dander, E., Otero, K., Barberis, L., Luini, W., et al. (2004). Defective dendritic cell migration and activation of adaptive immunity in P13Kgamma-deficient mice. Embo J. 23, 3505-3515. doi: 10.1038/sj.emboj.7600361
20. Dituri, F., Mazzocca, A., Lupo, L., Edling, C. E., Azzariti, A., Antonaci, S., et al. (2012). PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int. J. Cancer 130, 2505-2513. doi: 10.1002/ijc.26319
21. Edling, C. E., Selvaggi, F., Buus, R., Maffucci, T., Di Sebastiano, P., Friess, H., et al. (2010). Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin. Cancer Res. 16, 4928-4937. doi: 10.1158/1078-0432.CCR-10-1210
22. Edling, C. E., Selvaggi, F., Ghonaim, R., Maffucci, T., and Falasca, M. (2014). Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol. Ther. 15, 524-532. doi: 10.4161/cbt.28018
23. Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., and Flavell, R. A. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 13, 759-771. doi: 10.1038/nrc3611
24. Falasca, M. (2010). PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des. 16, 1410-1416. doi: 10.2174/138161210791033950
25. Falasca, M. (2011). Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism and drug development. Curr. Med. Chem. 18, 2673. doi: 10.2174/092986711796011210
26. Falasca, M., and Maffucci, T. (2007). Role of class II phosphoinositide 3-kinase in cell signalling. Biochem. Soc. Trans. 35, 211-214. doi: 10.1042/BST0350211
27. Falasca, M., and Maffucci, T. (2012). Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem J. 443, 587-601. doi: 10.1042/BJ20120008
28. Falasca, M., Selvaggi, F., Buus, R., Sulpizio, S., and Edling, C. E. (2011). Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials. Anticancer Agents Med. Chem. 11, 455-463. doi: 10.2174/187152011795677382
29. Fyffe, C., Buus, R., and Falasca, M. (2013). Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms. Curr. Pharm. Des. 19, 680-686. doi: 10.2174/138161213804581873
30. Gonzalez-Garcia, A., Sanchez-Ruiz, J., Flores, J. M., and Carrera, A. C. (2010). Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis associated cancer. Gastroenterology 138, 1374-1383. doi: 10.1053/j.gastro.2009.12.001
31. Gore, J., and Korc, M. (2014). Pancreatic cancer stroma: friend or foe? Cancer Cell 25, 711-712. doi: 10.1016/j.ccr.2014.05.026
32. Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L. K., Cain, R. J., Salpekar, A., et al. (2008). Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453, 662-666. doi: 10.1038/nature06892
33. Hamada, K., Sasaki, T., Koni, P. A., Natsui, M., Kishimoto, H., Sasaki, J., et al. (2005). The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev. 19, 2054-2065. doi: 10.1101/gad.1308805
34. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
35. Haqq, J., Howells, L. M., Garcea, G., Metcalfe, M. S., Steward, W. P., and Dennison, A. R. (2014). Pancreatic stellate cells and pancreas cancer: Current perspectives and future strategies. Eur. J. Cancer. 50, 2570-2582. doi: 10.1016/j.ejca.2014.06.021
36. He, G., and Karin, M. (2011). NF-κ B and STAT3-key players in liver inflammation and cancer. Cell Res. 21, 159-168. doi: 10.1038/cr.2010.183
37. Heller, R., Chang, Q., Ehrlich, G., Hsieh, S. N., Schoenwaelder, S. M., Kuhlencordt, P. J., et al. (2008). Overlapping and distinct roles for PI3Kbeta and gamma isoforms in S1P-induced migration of human and mouse endothelial cells. Cardiovasc. Res. 80, 96-105. doi: 10.1093/cvr/cvn159
38. Hickey, F. B., and Cotter, T. G. (2006). BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J. Biol. Chem. 281, 2441-2450. doi: 10.1074/jbc.M511173200
39. Hirsch, E., Bosco, O., Tropel, P., Laffargue, M., Calvez, R., Altruda, F., et al. (2001). Resistence to thromboembolism in P13Kgamma-deficient mice. Faseb J. 15, 2019-2021.
40. Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A., and Martini, M. (2014). PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Oncogene 33, 3083-3090. doi: 10.1038/onc.2013.265
41. Hirsch, E., Katanaev, V. L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., et al. (2000). Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287, 1049-1053. doi: 10.1126/science.287.5455.1049
42. Hruban, R. H., Goggins, M., Parsons, J., and Kern, S. E. (2000). Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969-7292.
43. Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., et al. (2005). PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat. Med. 11, 507-514. doi: 10.1038/nm1232
44. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90. doi: 10.3322/caac.20107
45. Kang, S., Denley, A., Vanhaesebroeck, B., and Vogt, P. K. (2006). Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 103, 1289-1294. doi: 10.1073/pnas.0510772103
46. Karagozian, R., Derdák, Z., and Baffy, G. (2014). Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63, 607-617. doi: 10.1016/j.metabol.2014.01.011
47. Khwaja, A., Rodriguez-Viciana, P., Wennström, S., Warne, P. H., and Downward, J. (1997). Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16, 2783-2793. doi: 10.1093/emboj/16.10.2783
48. Knobbe, C. B., and Reifenberger, G. (2003). Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507-518. doi: 10.1111/j.1750-3639.2003.tb00481.x
49. Kobayashi, N., Ueki, K., Okazaki, Y., Iwane, A., Kubota, N., Ohsugi, M., et al. (2011). Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 108, 5753-5758. doi: 10.1073/pnas.1016430108
50. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P., Downward, J., and Parker, P. J. (1994). The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 4, 798-806. doi: 10.1016/S0960-9822(00)00177-9
51. Kuper, H., Tzonou, A., Kaklamani, E., Hsieh, C. C., Lagiou, P., Adami, H. O., et al. (2000). Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int. J. Cancer 85, 498-502. doi: 10.1002/(SICI)1097-0215(20000215)85:4<498::AID-IJC9>3.0.CO;2-F
52. Lee, J. J., Perera, R. M., Wang, H., Wu, D. C., Liu, X. S., Han, S., et al. (2014). Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc. Natl. Acad. Sci. U.S.A. 111, E3091-E3100. doi: 10.1073/pnas.1411679111
53. Li, D., Xie, K., Wolff, R., and Abbruzzese, J. L. (2004). Pancreatic cancer. Lancet 363, 1049-1057. doi: 10.1016/S0140-6736(04)15841-8
54. Liu, P., Morrison, C., Wang, L., Xiong, D., Vedell, P., Cui, P., et al. (2012). Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33, 1270-1276. doi: 10.1093/carcin/bgs148
55. Lockhart, A. C., Rothenberg, M. L., and Berlin, J. D. (2005). Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 128, 1642-1654. doi: 10.1053/j.gastro.2005.03.039
56. Luo, J., Manning, B. D., and Cantley, L. C. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262. doi: 10.1016/S1535-6108(03)00248-4
57. Madeddu, P., Kraenkel, N., Barcelos, L. S., Siragusa, M., Campagnolo, P., Oikawa, A., et al. (2008). Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscler. Thromb. Vasc. Biol. 28, 68-76. doi: 10.1161/ATVBAHA.107.145573
58. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863. doi: 10.1158/1535-7163.MCT-08-0017
59. Marchesi, F., Monti, P., Leone, B. E., Zerbi, A., Vecchi, A., Piemonti, L., et al. (2004). Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 64, 8420-8427. doi: 10.1158/0008-5472.CAN-04-1343
60. Møller, H., Mellemgaard, A., Lindvig, K., and Olsen, J. H. (1994). Obesity and cancer risk: a Danish record-linkage study. Eur. J. Cancer. 30A, 344-350. doi: 10.1016/0959-8049(94)90254-2
61. Monterrubio, M., Mellado, M., Carrera, A. C., and Rodríguez-Frade, J. M. (2009). PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion. Biochem. Biophys. Res. Commun. 388, 199-204. doi: 10.1016/j.bbrc.2009.07.153
62. Morello, F., Perino, A., and Hirsch, E. (2009). Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc. Res. 82, 261-271. doi: 10.1093/cvr/cvn325
63. Moskaluk, C. A., Hruban, R. H., and Kern, S. E. (1997). p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 57, 2140-2143.
64. Nguyen, D. X., Bos, P. D., and Massagué, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284. doi: 10.1038/nrc2622
65. Nguyen, D. X., and Massague, J. (2007). Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8, 341-352. doi: 10.1038/nrg2101
66. Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R., et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734. doi: 10.1016/j.ccr.2014.04.005
67. Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., et al. (2004). P13Kgamma modulates the cardiac response to chronic pressure overload by distinct Kinase-dependent and -independent effects. Cell 118, 375-387. doi: 10.1016/j.cell.2004.07.017
68. Pomel, V., Klicic, J., Covini, D., Church, D. D., Shaw, J. P., Roulin, K., et al. (2006). Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 49, 3857-3871. doi: 10.1021/jm0601598
69. Ptasznik, A., Prossnitz, E. R., Yoshikawa, D., Smrcka, A., Traynor-Kaplan, A. E., and Bokoch, G. M. (1996). A tyrosine kinase signaling pathway accounts for the majority of phosphatidylinositol 3,4,5-trisphosphate formation in chemoattractant-stimulated human neutrophils. J. Biol. Chem. 271, 25204-25207. doi: 10.1074/jbc.271.41.25204
70. Quail, D. F., and Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437. doi: 10.1038/nm.3394
71. Randis, T. M., Puri, K. D., Zhou, H., and Diacovo, T. G. (2008). Role of P13Kdelta and P13Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur. J. Immunol. 38, 1215-1224. doi: 10.1002/eji.200838266
72. Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., et al. (2007). Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840-5850. doi: 10.1158/0008-5472.CAN-06-4615
73. Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., and Zwahlen, M. (2008). Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569-578. doi: 10.1016/S0140-6736(08)60269-X
74. Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., et al. (2014). Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735-747. doi: 10.1016/j.ccr.2014.04.021
75. Ryder, S. D. (2003). Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 52(Suppl. 3), iii1-iii8. doi: 10.1136/gut.52.suppl_3.iii1
76. Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., and Staunton, D. E. (2003). Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 170, 2647-2654. doi: 10.4049/jimmunol.170.5.2647
77. Samanic, C., Chow, W. H., Gridley, G., Jarvholm, B., and Fraumeni, J. F. Jr. (2006). Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17, 901-909. doi: 10.1007/s10552-006-0023-9
78. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554. doi: 10.1126/science.1096502
79. Sasaki, T., Irie-Sasaki, J., Horie, Y., Bachmaier, K., Fata, J. E., Li, M., et al. (2000). Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature 406, 897-902. doi: 10.1038/35022585
80. Sasaki, T., Irie-Sasaki, J., Horie, Y., Bachmaier, K., Fata, J. E., Li, M., et al. (2003). Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature 426, 584. doi: 10.1038/nature02203
81. Sawyer, C., Sturge, J., Bennett, D. C., O'Hare, M. J., Allen, W. E., Bain, J., et al. (2003). Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res. 63, 1667-1675.
82. Schlesinger, S., Aleksandrova, K., Pischon, T., Fedirko, V., Jenab, M., Trepo, E., et al. (2013). Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int. J. Cancer 132, 645-657. doi: 10.1002/ijc.27645
83. Schlieman, M. G., Fahy, B. N., Ramsamooj, R., Beckett, L., and Bold, R. J. (2003). Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer. 89, 2110-2115. doi: 10.1038/sj.bjc.6601396
84. Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., et al. (2011). Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 19, 715-727. doi: 10.1016/j.ccr.2011.04.016
85. Schneider, G., Siveke, J. T., Eckel, F., and Schmid, R. M. (2005). Pancreatic cancer: basic and clinical aspects. Gastroenterology 128, 1606-1625. doi: 10.1053/j.gastro.2005.04.001
86. Shen, Y. C., Lin, Z. Z., Hsu, C. H., Hsu, C., Shao, Y. Y., and Cheng, A. L. (2013). Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2, 345-364. doi: 10.1159/000343850
87. Singh, S., Singh, P. P., Roberts, L. R., and Sanchez, W. (2014). Chemopreventive strategies in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 11, 45-54. doi: 10.1038/nrgastro.2013.143
88. So, L., and Fruman, D. A. (2012). PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem. J. 442, 465-481. doi: 10.1042/BJ20112092
89. Sujobert, P., Bardet, V., Cornillet-Lefebvre, P., Hayflick, J. S., Prie, N., Verdier, F., et al. (2005). Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106, 1063-1066. doi: 10.1182/blood-2004-08-3225
90. Sun, B., and Karin, M. (2014). The therapeutic value of targeting inflammation in gastrointestinal cancers. Trends Pharmacol. Sci. 35, 349-357. doi: 10.1016/j.tips.2014.04.011
91. Takeda, A., Osaki, M., Adachi, K., Honjo, S., and Ito, H. (2004). Role of the phosphatidylinositol 3′-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 28, 353-358. doi: 10.1097/00006676-200404000-00026
92. Thomas, M. B., Jaffe, D., Choti, M. M., Belghiti, J., Curley, S., Fong, Y., et al. (2010). Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 28, 3994-4005. doi: 10.1200/JCO.2010.28.7805
93. Thomas, M. B., O'Beirne, J. P., Furuse, J., Chan, A. T., Abou-Alfa, G., and Johnson, P. (2008). Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann. Surg. Oncol. 15, 1008-1014. doi: 10.1245/s10434-007-9705-0
94. Thrumurthy, S. G., Chaudry, M. A., Hochhauser, D., and Mughal, M. (2013). The diagnosis and management of gastric cancer. BMJ 347, f6367. doi: 10.1136/bmj.f6367
95. Tibolla, G., Piñeiro, R., Chiozzotto, D., Mavrommati, I., Wheeler, A. P., Norata, G. D., et al. (2013). Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. PLoS ONE 8:e53808. doi: 10.1371/journal.pone.0053808.
96. Traynor-Kaplan, A. E., Harris, A. L., Thompson, B. L., Taylor, P., and Sklar, L. A. (1988). An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature 334, 353-356. doi: 10.1038/334353a0
97. Turati, F., Talamini, R., Pelucchi, C., Polesel, J., Franceschi, S., Crispo, A., et al. (2013). Metabolic syndrome and hepatocellular carcinoma risk. Br. J. Cancer 108, 222-228. doi: 10.1038/bjc.2012.492
98. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell. Biol. 11, 329-341. doi: 10.1038/nrm2882
99. Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., et al. (2001). Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70, 535-602. doi: 10.1146/annurev.biochem.70.1.535
100. Van Meeteren, L. A., and Moolenaar, W. H. (2007). Regulation and biological activities of the autotaxin-LPA axis. Prog. Lipid Res. 46, 145-160. doi: 10.1016/j.plipres.2007.02.001
101. Venable, J. D., Ameriks, M. K., Blevitt, J. M., Thurmond, R. L., and Fung-Leung, W. P. (2010). Phosphoinositide 3-kinase gamma (P13Kgamma) inhibitors for the treatment of inflammation and autoimmune disease. Recent Pat. Inflamm. Allergy Drug Discov. 4, 1-15. doi: 10.2174/187221310789895603
102. Ward, P. S., and Thompson, C. B. (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297-308. doi: 10.1016/j.ccr.2012.02.014
103. Welti, J., Loges, S., Dimmeler, S., and Carmeliet, P. (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200. doi: 10.1172/JCI70212
104. Winkler, D. G., Faia, K. L., DiNitto, J. P., Ali, J. A., White, K. F., Brophy, E. E., et al. (2013). PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364-1374. doi: 10.1016/j.chembiol.2013.09.017
105. Wolk, A., Gridley, G., Svensson, M., Nyrén, O., McLaughlin, J. K., Fraumeni, J. F., et al. (2001). A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 12, 13-21. doi: 10.1023/A:1008995217664
106. Xie, Y., Abel, P. W., Kirui, J. K., Deng, C., Sharma, P., Wolff, D. W., et al. (2013). Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion. Biochem. Pharmacol. 85, 1454-1462. doi: 10.1016/j.bcp.2013.03.001
107. Yamamoto, S., Tomita, Y., Hoshida, Y., Morooka, T., Nagano, H., Dono, K., et al. (2004). Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 10, 2846-2850. doi: 10.1158/1078-0432.CCR-02-1441
108. Yuan, C., Bao, Y., Wu, C., Kraft, P., Ogino, S., Ng, K., et al. (2013). Prediagnostic body mass index and pancreatic cancer survival. J. Clin. Oncol. 31, 4229-4234. doi: 10.1200/JCO.2013.51.7532
109. Yuan, T. L., and Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510. doi: 10.1038/onc.2008.245
110. Zhang, Y. (2013). Epidemiology of esophageal cancer. World J. Gastroenterol. 19, 5598-5606. doi: 10.3748/wjg.v19.i34.5598
111. Zhao, L., and Vogt, P. K. (2008). Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486-5496. doi: 10.1038/onc.2008.244
112. Zhou, Q., Lui, V. W., and Yeo, W. (2011). Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 7, 1149-1167. doi: 10.2217/fon.11.95
113. Zvelebil, M. J., Waterfield, M. D., and Shuttleworth, S. J. (2008). Structural analysis of P13-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch. Biochem. Biophys. 477, 404-410. doi: 10.1016/j.abb.2008.06.024